Core Viewpoint - Apimeds Pharmaceuticals US, Inc. has merged with MindWave Innovations Inc, creating a dual-growth enterprise in advanced biotechnology and institutional sectors [1] Company Overview - Apimeds Pharmaceuticals completed its IPO in May 2025 [1] - The merger agreement between Apimeds and MindWave outlines the terms of the transaction [1] Industry Implications - The merger signifies a strategic move to enhance capabilities in advanced biotechnology [1] - The combination of Apimeds and MindWave is expected to foster growth in both companies' operational areas [1]